script.reportAU
Respiratory

Umeclidinium bromide

Brand: Incruse® Ellipta®

PBAC's latest decision on Umeclidinium bromide: Recommended with restriction (2014). Considered for Treatment of chronic obstructive pulmonary disease (COPD) as monotherapy, in combination with a long-acting beta agonist (LABA), and in combination with a LABA and an inhaled corticosteroid (ICS).

PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014

Eligible population

Adult patients with chronic obstructive pulmonary disease (COPD) of mild to severe severity.

Therapy area
Respiratory
Line of therapy
First-line
Evidence base
Meta-analysis
Primary endpoint
FEV1
Pivotal trial size
835 patients
Key trials
AC4115408, DB2113373, SHINE, Brusasco 2003, Casaburi 2000, Casaburi 2002, Chan 2007, Covelli 2005, Donohue 2002, Donohue 2010, Garcia 2007, GLOW2, Moita 2008, Niewoehner 2005, UPLIFT, TIPHON, Verkindre 2006, Vogelmeier 2008
Comparator
tiotropium
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated as the drug is claimed to be equi-effective with tiotropium.

Similar precedents

Open on full dashboard →